Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population
-
Published:2023-07
Issue:7
Volume:41
Page:328.e15-328.e23
-
ISSN:1078-1439
-
Container-title:Urologic Oncology: Seminars and Original Investigations
-
language:en
-
Short-container-title:Urologic Oncology: Seminars and Original Investigations
Author:
Millan BradenORCID, Breau Rodney H., Mallick Ranjeeta, Wood Lori, Rendon Ricardo, Finelli Antonio, So Alan I., Lavallée Luke T., Pouliot Frédéric, Bhindi Bimal, Heng Daniel, Drachenberg Darrel, Tanguay Simon, Dean Lucas, Basappa Naveen S., Lattouf Jean-Baptiste, Bjarnason George, Lalani Aly-Khan, Kapoor Anil
Reference21 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021 2. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline—part I;Campbell;J Urol,2021 3. Preoperative predictors of pathological lymph node metastasis in patients with renal cell carcinoma undergoing retroperitoneal lymph node dissection;Babaian;J Urol,2015 4. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial;Haas;Lancet,2016 5. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial;Gross-Goupil;Ann Oncol,2018
|
|